Cargando…
Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum anti-TUB...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852414/ https://www.ncbi.nlm.nih.gov/pubmed/29448203 http://dx.doi.org/10.1016/j.tranon.2018.01.016 |
_version_ | 1783306566888325120 |
---|---|
author | Martinelli, Enrica Fattorossi, Andrea Battaglia, Alessandra Petrillo, Marco Raspaglio, Giuseppina Zannoni, Gian Franco Fanelli, Mara Gallo, Daniela Scambia, Giovanni |
author_facet | Martinelli, Enrica Fattorossi, Andrea Battaglia, Alessandra Petrillo, Marco Raspaglio, Giuseppina Zannoni, Gian Franco Fanelli, Mara Gallo, Daniela Scambia, Giovanni |
author_sort | Martinelli, Enrica |
collection | PubMed |
description | Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum anti-TUBB3 antibodies was investigated in 49 untreated OC patients and 44 healthy individuals by an in-house developed ELISA that used recombinant TUBB3 as the antigen. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of the assay. Anti-TUBB3 antibodies discriminated OC patients and healthy individuals with excellent sensitivity and specificity (91.8% and 90.9%, respectively). In multivariate analysis, anti-TUBB3 antibody level emerged as an independent prognostic factor for progression free and overall survival. The ELISA was then optimized using a biotin-labeled TUBB3 C-terminal peptide(424-450) instead of recombinant TUBB3 as the antigen and streptavidin-coated plates. The diagnostic role of the anti-TUBB3 antibodies was studied in an independent series of 99 OC patients and 80 gynecological benign disease patients. ROC-curve analysis showed a valuable diagnostic potential for serum anti-TUBB3 antibodies to identify OC patients with higher sensitivity and specificity (95.3% and 97.6%, respectively). Overall, our results provide evidence that preoperative anti-TUBB3 antibody level is a promising diagnostic and prognostic biomarker for the management of OC patients. |
format | Online Article Text |
id | pubmed-5852414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58524142018-03-16 Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer Martinelli, Enrica Fattorossi, Andrea Battaglia, Alessandra Petrillo, Marco Raspaglio, Giuseppina Zannoni, Gian Franco Fanelli, Mara Gallo, Daniela Scambia, Giovanni Transl Oncol Original article Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum anti-TUBB3 antibodies was investigated in 49 untreated OC patients and 44 healthy individuals by an in-house developed ELISA that used recombinant TUBB3 as the antigen. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of the assay. Anti-TUBB3 antibodies discriminated OC patients and healthy individuals with excellent sensitivity and specificity (91.8% and 90.9%, respectively). In multivariate analysis, anti-TUBB3 antibody level emerged as an independent prognostic factor for progression free and overall survival. The ELISA was then optimized using a biotin-labeled TUBB3 C-terminal peptide(424-450) instead of recombinant TUBB3 as the antigen and streptavidin-coated plates. The diagnostic role of the anti-TUBB3 antibodies was studied in an independent series of 99 OC patients and 80 gynecological benign disease patients. ROC-curve analysis showed a valuable diagnostic potential for serum anti-TUBB3 antibodies to identify OC patients with higher sensitivity and specificity (95.3% and 97.6%, respectively). Overall, our results provide evidence that preoperative anti-TUBB3 antibody level is a promising diagnostic and prognostic biomarker for the management of OC patients. Neoplasia Press 2018-02-20 /pmc/articles/PMC5852414/ /pubmed/29448203 http://dx.doi.org/10.1016/j.tranon.2018.01.016 Text en © 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Martinelli, Enrica Fattorossi, Andrea Battaglia, Alessandra Petrillo, Marco Raspaglio, Giuseppina Zannoni, Gian Franco Fanelli, Mara Gallo, Daniela Scambia, Giovanni Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer |
title | Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer |
title_full | Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer |
title_fullStr | Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer |
title_full_unstemmed | Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer |
title_short | Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer |
title_sort | preoperative anti-class iii β-tubulin antibodies as relevant clinical biomarkers in ovarian cancer |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852414/ https://www.ncbi.nlm.nih.gov/pubmed/29448203 http://dx.doi.org/10.1016/j.tranon.2018.01.016 |
work_keys_str_mv | AT martinellienrica preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT fattorossiandrea preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT battagliaalessandra preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT petrillomarco preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT raspagliogiuseppina preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT zannonigianfranco preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT fanellimara preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT gallodaniela preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer AT scambiagiovanni preoperativeanticlassiiibtubulinantibodiesasrelevantclinicalbiomarkersinovariancancer |